Theriva Biologics Past Earnings Performance
Past criteria checks 0/6
Theriva Biologics has been growing earnings at an average annual rate of 4.1%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
4.1%
Earnings growth rate
67.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -46.2% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Theriva Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -18 | 8 | 14 |
| 30 Sep 23 | 0 | -19 | 11 | 13 |
| 30 Jun 23 | 0 | -21 | 12 | 12 |
| 31 Mar 23 | 0 | -20 | 10 | 12 |
| 31 Dec 22 | 0 | -20 | 8 | 12 |
| 30 Sep 22 | 0 | -19 | 8 | 11 |
| 30 Jun 22 | 0 | -17 | 7 | 11 |
| 31 Mar 22 | 0 | -16 | 7 | 9 |
| 31 Dec 21 | 0 | -23 | 6 | 8 |
| 30 Sep 21 | 0 | -21 | 5 | 6 |
| 30 Jun 21 | 0 | -20 | 5 | 5 |
| 31 Mar 21 | 0 | -21 | 5 | 5 |
| 31 Dec 20 | 0 | -13 | 5 | 5 |
| 30 Sep 20 | 0 | -13 | 5 | 6 |
| 30 Jun 20 | 0 | -15 | 5 | 9 |
| 31 Mar 20 | 0 | -16 | 5 | 10 |
| 31 Dec 19 | 0 | -16 | 5 | 11 |
| 30 Sep 19 | 0 | -28 | 4 | 11 |
| 30 Jun 19 | 0 | -26 | 5 | 10 |
| 31 Mar 19 | 0 | -27 | 5 | 11 |
| 31 Dec 18 | 0 | -25 | 6 | 12 |
| 30 Sep 18 | 0 | -8 | 7 | 13 |
| 30 Jun 18 | 0 | -22 | 7 | 15 |
| 31 Mar 18 | 0 | -22 | 7 | 16 |
| 31 Dec 17 | 0 | -22 | 8 | 19 |
| 30 Sep 17 | 0 | -27 | 9 | 22 |
| 30 Jun 17 | 0 | -18 | 9 | 25 |
| 31 Mar 17 | 0 | -19 | 10 | 27 |
| 31 Dec 16 | 0 | -27 | 10 | 29 |
| 30 Sep 16 | 0 | -36 | 9 | 31 |
| 30 Jun 16 | 0 | -34 | 9 | 34 |
| 31 Mar 16 | 0 | -42 | 9 | 35 |
| 31 Dec 15 | 0 | -44 | 8 | 33 |
| 30 Sep 15 | 0 | -39 | 7 | 29 |
| 30 Jun 15 | 0 | -37 | 7 | 23 |
| 31 Mar 15 | 0 | -28 | 7 | 18 |
| 31 Dec 14 | 0 | -20 | 6 | 14 |
| 30 Sep 14 | 0 | -18 | 5 | 12 |
| 30 Jun 14 | 0 | -16 | 6 | 10 |
| 31 Mar 14 | 0 | -14 | 5 | 8 |
| 31 Dec 13 | 0 | -12 | 5 | 7 |
| 30 Sep 13 | 0 | -20 | 6 | 14 |
Quality Earnings: TOVX is currently unprofitable.
Growing Profit Margin: TOVX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TOVX is unprofitable, but has reduced losses over the past 5 years at a rate of 4.1% per year.
Accelerating Growth: Unable to compare TOVX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TOVX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: TOVX has a negative Return on Equity (-46.22%), as it is currently unprofitable.